Dr. Zorba Paster critiques the Pentagon’s new testosterone screening for service members, arguing that current norms are outdated and replacement therapy lacks robust evidence for enhancing combat readiness. He highlights that while testosterone aids those with documented deficiencies, it offers minimal benefit for erectile function compared to PDE5 inhibitors and carries significant risks like reduced sperm production and worsened sleep apnea. Paster urges the Defense Department to conduct proper scientific studies rather than mandating widespread treatment without proven performance benef…